Phase III data shows Novartis drug Afinitor benefits in non-cancerous tumours ... pharmabiz.com Novartis announced that the data published in The Lancet shows that patients on Afinitor (everolimus) tablets with non-cancerous kidney tumours known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant ... Kidneys Sometimes Removed Unnecessarily Due to Misdiagnosis of Genetic ... Novartis Says Phase III Data In Lancet Show Significant Benefit Of Afinitor Novartis says Afinitor reduces tumors in rare genetic disease |
